Phase 1 trial shows linear pharmacokinetics and good tolerability for HRS-8427 in healthy Chinese adultsCan a new antibiotic candidate be safely tested in people? Early results look promising

Antimicrobial agents and chemotherapy Published April 4, 2026 Study authors: Yin Tengrui, Qu Biao, Zhang Qian, Xu Sheng, Wu Yijue, Jiang Hao, Huang Yuanyuan, Hu Wei PubMed ↗ NCT07070375 ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider HRS-8427 pharmacokinetics linear and well-tolerated in healthy adults, but efficacy is unknown.

This phase 1 randomized controlled trial assessed the pharmacokinetics, safety, and tolerability of the novel anti-carbapenem-resistant cephalosporin HRS-8427 in 79 healthy Chinese adults. The study used single ascending doses (400-6,000 mg) and multiple ascending doses (1,000-3,000 mg every 8 hours). The setting and comparator were not reported.

Pharmacokinetic analysis showed approximately dose-proportional increases in Cmax and AUC across the single-dose range of 400-6,000 mg, though drug exposure increased slightly less than the dose. The mean plasma half-life ranged from 3.89 to 4.28 hours. The drug was primarily excreted unchanged in urine (62.13% to 71.12% of the dose). With multiple dosing every 8 hours, there was minimal systemic accumulation of Cmax and AUC, and pharmacokinetics did not change with repeated administration.

Regarding safety, 62 treatment-emergent adverse events occurred in 29 subjects, yielding an incidence of 36.7% (29/79). No serious adverse events were observed. Three subjects withdrew due to adverse events (one in the 2,000 mg single-dose group and two in the 3,000 mg multi-dose group). The study concluded that both single and multiple intravenous doses, up to 6,000 mg and 2,000 mg respectively, were well tolerated.

Key limitations include the early-phase design, the healthy volunteer population, and the absence of efficacy data or a reported comparator. The funding and conflicts of interest were not reported. Practice relevance is limited as this is a first-in-human safety and pharmacokinetic study; clinical utility for treating infections remains to be established in patient trials.

When bacteria become resistant to our best antibiotics, we desperately need new options. A recent study took a first, careful look at a potential new drug called HRS-8427, designed to fight tough, resistant infections. In 79 healthy Chinese adults, researchers tested how the drug moves through and leaves the body at different doses, and most importantly, whether it was safe.

The results are an encouraging early sign. The drug's levels in the blood increased roughly in line with the dose given, which is what doctors want to see for predictable dosing. It was cleared from the body relatively quickly, mostly through urine. When given multiple times a day, it didn't build up to problematic levels. On the safety side, while 29 people reported side effects—and three dropped out because of them—there were no serious or life-threatening events reported.

It's vital to remember what this study is and isn't. This was a Phase 1 trial, the very first test in humans. Its sole job was to check basic safety and how the drug behaves in healthy people. We have no idea if HRS-8427 can treat a single infection. The real test—whether it helps patients who are actually sick—is still to come. For now, it's a necessary and positive first step on a very long road.

What this means for you:

A new antibiotic candidate shows early safety promise, but we don't know if it works yet.

Study Details

Study typeRct

EvidenceLevel 2

PublishedApr 2026

PMID41773934

TrialNCT07070375

View Original Abstract ↓

HRS-8427 is a novel parenteral siderophore cephalosporin that shows potent efficacy against various gram-negative bacteria, including carbapenem-resistant strains, and in preclinical models of infection. It underwent a single-dose ascending study (400-6,000 mg) and a multiple-dose ascending study (1,000-3,000 mg q8h) in healthy Chinese adults to evaluate pharmacokinetics (PK), safety, and tolerability. A total of 62 treatment-emergent adverse events (TEAEs) occurred in 29 subjects during the treatment period, resulting in a TEAE incidence of 36.7% (29/79). There were no serious adverse events (AEs) observed in either study. Three subjects (one in the 2,000 mg single-dose group and two in the 3,000 mg multi-dose group) withdrew from the trial due to AEs. Approximately dose-proportional increases in the maximum plasma concentration () and the area under the concentration-time curve (AUC) were observed across the single-dose range of 400-6,000 mg, although the drug exposure increased slightly less than the dose. The mean plasma half-life of HRS-8427 was 3.89 to 4.28 h. HRS-8427 was primarily excreted unchanged in the urine (62.13% to 71.12% of the dose). There was minimal systemic accumulation of and AUC by dosing q8h, and the PK of HRS-8427 did not change with multiple dosing. This study indicates that both single and multiple intravenous doses of HRS-8427, up to 6,000 mg and 2,000 mg, respectively, are well tolerated in healthy subjects and show generally linear pharmacokinetics at doses up to 6,000 mg.This study is registered with the Chinese Clinical Trial registry as ChiCTR2200062570, and ClinicalTrials.gov as NCT07070375, NCT06144060, NCT06569056, NCT06841731, NCT07049562, NCT07049107, and NCT07073157.

Phase 1 trial shows linear pharmacokinetics and good tolerability for HRS-8427 in healthy Chinese adultsCan a new antibiotic candidate be safely tested in people? Early results look promising

Study Details

Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures

Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk

Clinical research that matters. Delivered to your inbox.

Phase 1 trial shows linear pharmacokinetics and good tolerability for HRS-8427 in healthy Chinese adultsCan a new antibiotic candidate be safely tested in people? Early results look promising

Study Details

Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures

Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk

Clinical research that matters. Delivered to your inbox.

Related in Infectious Disease

From Other Specialties